BSE Live
Mar 19, 16:01Prev. Close
167.95
Open Price
165.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 19, 15:58Prev. Close
167.89
Open Price
167.00
Bid Price (Qty.)
161.41 (229)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Marksans Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 243.26 | 171.89 | 132.04 | 134.51 | 124.33 | |
| Net CashFlow From Operating Activities | 31.02 | 34.05 | 51.73 | 50.97 | 107.07 | |
| Net Cash Used In Investing Activities | 17.24 | -114.22 | -194.62 | -8.40 | 8.82 | |
| Net Cash Used From Financing Activities | -29.92 | -26.22 | 210.02 | 75.86 | -13.53 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 18.34 | -106.38 | 67.12 | 118.44 | 102.36 | |
| Cash And Cash Equivalents Begin of Year | 41.93 | 148.31 | 81.19 | 105.61 | 3.35 | |
| Cash And Cash Equivalents End Of Year | 60.27 | 41.93 | 148.31 | 224.05 | 105.71 |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth